PDEX
Pro-Dex, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$71.67
+16.06%Year over year
Reported trailing growth
- Revenue
- +16.4%
- EBITDA
- +41.4%
- EBIT
- -7.6%
- EPS
- +29.4%
- Free cash flow
- +498.5%
- Operating cash flow
- +1601.4%
Forward estimates
Based on analyst estimates
- Revenue
- +8.4%
- EBITDA
- -28.9%
- EPS
- -24.6%
Three-year CAGR
- Revenue
- +16.6%
- EBITDA
- +27.1%
- EBIT
- +27.8%
- Net income
- +25.2%
- EPS
- +29.4%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026